newsfilter
← Latest News
Business Wire·

Pear Therapeutics Presents Real-World Data Showing Reduction in Healthcare Resource Utilization and Associated Costs in Adults Using Somryst® at ISPOR Europe

Somryst® is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of chronic insomnia Analysis demonstrated potential per-patient cost reductions over 24 months of $8,202 compared to